Business Context and Reporting Period
Company: Armata Pharmaceuticals, Inc. (ARMP)
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2026
Reporting Period: Single event date (February 23, 2026)
The filing serves as a Regulation FD disclosure regarding a significant regulatory milestone for the Company's lead product candidate.
Key Financial Metrics
This Form 8-K is a current report focused on a regulatory event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the receipt of a regulatory designation from the U.S. Food and Drug Administration (FDA):
- Product: AP-SA02, an intravenously-administered Staphylococcus aureus multi-phage product candidate.
- Designation: Qualified Infectious Disease Product (QIDP).
- Indication: Adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA).
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the FDA announcement but does not include specific forward-looking guidance, financial outlook, or management commentary within the body of this 8-K text.
Risks and Contingencies: The filing explicitly states that the information provided is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be incorporated by reference into other registration statements. No specific risks or contingencies are detailed in this excerpt.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the QIDP designation benefits and potential impact on the development timeline.
- Confirm the specific clinical trial phase of AP-SA02 at the time of designation.
- Review the Company's most recent 10-K or 10-Q for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the FDA's review process or changes to the development plan resulting from the QIDP status.